Celularity Completes Strategic Review Of 2023 Initiatives

Celularity Inc CELU:

• CELULARITY COMPLETES STRATEGIC REVIEW OF 2023 INITIATIVES, INCLUDING ANTICIPATED BIOMATERIALS PRODUCTION RAMP-UP AND PIPELINE PRIORITIZATION OF NEXT-GENERATION PRODUCT CANDIDATES

• CELULARITY INC - COMMERCIAL BIOMATERIALS BUSINESS, DEGENERATIVE DISEASE PROGRAMS CONTINUE TO GATHER MOMENTUM

• CELULARITY - NOTIFIED SUBSTANTIAL PORTION OF WORKFORCE THAT THEIR EMPLOYMENT MAY BE IMPACTED TO ACHIEVE STRATEGIC OBJECTIVES

• CELULARITY INC - HOPEFUL THAT THERE WILL BE NO NEED TO SUBSTANTIALLY REDUCE ITS HEADCOUNT

• CELULARITY INC - PLANS TO COMPLETE REQUIRED PRECLINICAL WORK ON ITS ECM PRODUCT CANDIDATE OVER NEXT SEVERAL MONTHS

• CELULARITY INC - ALSO IS CONDUCTING PRECLINICAL WORK IN KNEE OSTEOARTHRITIS (KOA) USING ITS PLACENTA-DERIVED EXOSOMES (PEXO)

• CELULARITY - TO CONTINUE TO PARTNER WITH IMUGENE TO UTILIZE NOVEL ONCARLYTICS TECHNOLOGY TO PRIME SOLID TUMOR CELLS TO EXPRESS CD19